Biosketch:
Howard Feldman, M.D., C.M., F.R.C.P.(C)
Howard Feldman, M.D., C.M., F.R.C.P.(C) is Professor and Head of the Division of Neurology University of British Columbia
and Vancouver Coastal Health, Vancouver, Canada. He is the Director of the Clinic for Alzheimer Disease and Related
Disorders at UBC Hospital and holds an appointment as Adjunct Professor at the McGill Centre for Studies in Aging in
Montreal.
In his research activities, Dr. Feldman has been active in both epidemiological and clinical diagnostic/therapeutic studies
in Alzheimer's disease. He has been been principal investigator for a number of large international studies with
cholinesterase inhibitors and other experimental therapeutics in AD and has had a strong focus on clinical trials
methodology and longitudinal course. His contribution to the dementia field also includes key scientific discoveries in the
area of the frontotemporal dementias. He has been involved the discovery of the progranulin gene for FTD as well as to
the determination of the constitutional protein in this disorder. These discoveries resulted in highly cited papers in both
Science and Nature in 2006. He has had consistent peer-reviewed funding for his research from the Canadian Institutes of
Health Research, the Alzheimer Society of Canada, and the National Institutes of Health.
Dr. Feldman’s work has published extensively in peer-reviewed professional journals, texts having more than 200
publications. He has lectured globally and received a number of awards for his research. One of his papers in Lancet
Neurology was the most downloaded in Science Direct for the journal in 2003.
He is a member of numerous professional societies, including the American Academy of Neurology, the Canadian
Neurological Sciences and the Canadian Consortium of Clinical Cognitive Research Centers (C5R) of which he is a former
president. He has been active as a member of the steering committee of the International Harmonization of Dementia
Drug Development and is a member of the Medical and Scientific Advisory Board of Alzheimer’s Disease International and
has been advisor to European Institute of Women’s Health. He serves on the editorial boards of numerous journals and has
been called on to peer review for a variety of international agencies. He has contributed on a number of occasions to the
development of regulatory guidelines in Canada for antidementia treatments.
and Vancouver Coastal Health, Vancouver, Canada. He is the Director of the Clinic for Alzheimer Disease and Related
Disorders at UBC Hospital and holds an appointment as Adjunct Professor at the McGill Centre for Studies in Aging in
Montreal.
In his research activities, Dr. Feldman has been active in both epidemiological and clinical diagnostic/therapeutic studies
in Alzheimer's disease. He has been been principal investigator for a number of large international studies with
cholinesterase inhibitors and other experimental therapeutics in AD and has had a strong focus on clinical trials
methodology and longitudinal course. His contribution to the dementia field also includes key scientific discoveries in the
area of the frontotemporal dementias. He has been involved the discovery of the progranulin gene for FTD as well as to
the determination of the constitutional protein in this disorder. These discoveries resulted in highly cited papers in both
Science and Nature in 2006. He has had consistent peer-reviewed funding for his research from the Canadian Institutes of
Health Research, the Alzheimer Society of Canada, and the National Institutes of Health.
Dr. Feldman’s work has published extensively in peer-reviewed professional journals, texts having more than 200
publications. He has lectured globally and received a number of awards for his research. One of his papers in Lancet
Neurology was the most downloaded in Science Direct for the journal in 2003.
He is a member of numerous professional societies, including the American Academy of Neurology, the Canadian
Neurological Sciences and the Canadian Consortium of Clinical Cognitive Research Centers (C5R) of which he is a former
president. He has been active as a member of the steering committee of the International Harmonization of Dementia
Drug Development and is a member of the Medical and Scientific Advisory Board of Alzheimer’s Disease International and
has been advisor to European Institute of Women’s Health. He serves on the editorial boards of numerous journals and has
been called on to peer review for a variety of international agencies. He has contributed on a number of occasions to the
development of regulatory guidelines in Canada for antidementia treatments.
